Laboratory Investigation

TABLE 1

FROM:

Validation of SELDI-TOF MS serum protein profiles for renal cell carcinoma in new populations

Judith Y M N Engwegen, Niven Mehra, John B A G Haanen, Johannes M G Bonfrer, Jan H M Schellens, Emile E Voest and Jos H Beijnen

BACK TO ARTICLE

Table 1. Patient and sample characteristics of sample sets 1 and 2 compared to those of Won and Tolson

 SexPatient age (years)RCC stageSurgical statusSample handlingSample age (years)
 RCCHCNon-RCC diseaseRCCHC   RCCHC
Set 125 M20 M57.1 (11.0)56.1 (8.79)16 IV33 presurgery30 min coagulation at RT2.94a (0.56)1.90 (0.034)
      4 III5 postsurgeryCentrifugation at 1900 g   
 15 F12 F   16 I/II2 unknownStorage at -30°C  
      4 Unknown    
Set 219 M7 M63.7b (10.2)42.9 (11.1)24 IV8 presurgery2–6 h coagulation at RT+ overnight at 4°C1.05 (0.55)1.28 (0.21)
 7 F20 F   2 II/III18 postsurgeryCentrifugation at 1500 g   
        Storage at -80°C  
Tolson15 M26 matched59.3 (14.6)Matched1 III25 presurgerySerum supernatant collectedNRNR
 10 F    6 IV Overnight coagulation at 4°C  
      7 II Storage at -70°C  
      11 I    
Won15 M+F6 M+F15 M+FNRNRNR15 presurgeryNRAll collected in same period

 Means (s.d.) for patient and sample age.

 Abbreviations: F: female, HC: healthy control, M: male, NR: not reported, RCC: renal cell carcinoma, RT: room temperature.

a  P<0.000 independent samples t-test.

b  P<0.000 nonparametric Mann–Whitney U-test.

BACK TO ARTICLE